Author

Gabrielle Link

Morgan Adams FoundationORCID 0009-0007-9472-7399Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Organism:mouse· 2 Assay:ChIP-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1

Frequent Co-Authors

Adam L. GreeniD· 4 shared Aaron J. KnoxiD· 1 shared Cameron L. LymaniD· 1 shared Daniel Jay BratiD· 1 shared Dolores HambardzumyaniD· 1 shared Eita UchidaiD· 1 shared Elise JakeliD· 1 shared Elizabeth Janko· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Adam L. GreenORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

BiophysicsChemical & Biomedical ImagingPeer-reviewedOct 30, 2026

An Open-Source, Excitation-Resolved UV-NIR Imaging Platform for Bioluminescence, Luminescence-Decay, and Chemical Discrimination Measurements

John M. Branning, Cameron L. Lyman, Isabella A. Hensley…·Kevin J. Cash

AURORA-MSI is an open-source multispectral imaging platform that enables excitation-resolved measurements of bioluminescence, luminescence decay, and chemical discrimination without photon-counting instrumentation.

DOI 10.1021/cbmi.6c00168

mouseplant (other)

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 18, 2026

Preclinical evaluation of ixazomib for high-risk pediatric brain tumors

Elizabeth Janko, Faye M. Walker, Mathew Slade…·Nathan A. Dahl

This study evaluates ixazomib's efficacy against high-risk pediatric brain tumors, finding it cytotoxic but with limited CNS penetration.

DOI 10.64898/2026.09.11.750478

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyPLoS ONEPeer-reviewedDec 22, 2025

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models

Yusuke Tomita, Gabrielle Link, Yi Ge…·Oren Josh Becher

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

1 citation

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyMolecular Cancer ResearchPeer-reviewedOct 18, 2024

PRMT5 maintains tumor stem cells to promote pediatric high-grade glioma tumorigenesis

John A. DeSisto, Ilango Balakrishnan, Aaron J. Knox…·Adam L. Green

This study identifies PRMT5 as essential for pediatric high-grade glioma growth by maintaining tumor stem cells, showing that its inhibition reduces self-renewal and improves survival in preclinical models.

4 citations

humanChIP-seq

𝕏 PostBluesky